NEXTBio Capital Management LP
13F Reported Value
ⓘ$217.4M
Holdings
22
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
NEXTBio Capital Management LP disclosed 22 positions worth $217.4M in its Form 13F-HR for Q2 2026, led by $PTGX (Protagonist Therapeutics, Inc) at 12.4% of the equity portfolio, followed by $STTK and $CMPS. During the quarter the fund opened 3 new positions and exited 5 — including a new stake in $PHVS and a full exit from $TERN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from NEXTBio Capital Management LP’s Form 13F-HR filing with the SEC under CIK 2038158.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 59.4#932
Quality
$26.9M219,333 sh - —
Quality
$25.9M3,727,348 sh - —
Quality
$25.1M1,775,759 sh - —
Quality
$16.8M312,496 sh - —
Quality
$16.4M889,164 sh - 33.9
Quality
$14.6M131,758 sh - —
Quality
$13.7M89,909 sh - 24.0
Quality
$11.1M183,225 sh - 7.4
Quality
$10.8M426,736 sh - —
Quality
$7.6M706,124 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Protagonist Therapeutics, Inc$PTGX | 59.4#932 | $26.9M | 219,333 |
 Shattuck Labs, Inc.$STTK | — | $25.9M | 3,727,348 |
 COMPASS Pathways plc$CMPS | — | $25.1M | 1,775,759 |
 Structure Therapeutics Inc.$GPCR | — | $16.8M | 312,496 |
 Vor Biopharma Inc.$VOR | — | $16.4M | 889,164 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9 | $14.6M | 131,758 |
 PALVELLA THERAPEUTICS, INC.$PVLA | — | $13.7M | 89,909 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $11.1M | 183,225 |
 Zenas BioPharma, Inc.$ZBIO | 7.4 | $10.8M | 426,736 |
 Oric Pharmaceuticals, Inc.$ORIC | — | $7.6M | 706,124 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of NEXTBio Capital Management LP's 22 positions.
Showing top 10 of 22 holdings.
Sector Allocation
Healthcare
$217.4M
Full Holdings — NEXTBio Capital Management LP (Q2 2026)
All 22 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PTGX | Protagonist Therapeutics, Inc | $26.9M | 12.4% | -4% | 59.4 |
| 2 | $STTK | Shattuck Labs, Inc. | $25.9M | 11.9% | +18% | — |
| 3 | $CMPS | COMPASS Pathways plc | $25.1M | 11.6% | -12% | — |
| 4 | $GPCR | Structure Therapeutics Inc. | $16.8M | 7.7% | +135% | — |
| 5 | $VOR | Vor Biopharma Inc. | $16.4M | 7.5% | -11% | — |
| 6 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $14.6M | 6.7% | +5% | 33.9 |
| 7 | $PVLA | PALVELLA THERAPEUTICS, INC. | $13.7M | 6.3% | +9% | — |
| 8 | $XENE | Xenon Pharmaceuticals Inc. | $11.1M | 5.1% | +0% | 24 |
| 9 | $ZBIO | Zenas BioPharma, Inc. | $10.8M | 5.0% | +0% | 7.4 |
| 10 | $ORIC | Oric Pharmaceuticals, Inc. | $7.6M | 3.5% | +35% | — |
| 11 |  $IVA | Inventiva S.A. | $6.8M | 3.1% | +34% | — |
| 12 |  $CBIO | CRESCENT BIOPHARMA, INC. | $6.7M | 3.1% | +0% | 9.6 |
| 13 |  $PCVX | Vaxcyte, Inc. | $6.2M | 2.9% | +13% | — |
| 14 |  $COGT | Cogent Biosciences, Inc. | $5.1M | 2.3% | -0% | — |
| 15 |  $VSTM | Verastem, Inc. | $5.0M | 2.3% | +0% | 29.7 |
| 16 |  $IRON | Disc Medicine, Inc. | $3.9M | 1.8% | +0% | — |
| 17 |  $PHVS | Pharvaris N.V. | $3.7M | 1.7% | NEW | — |
| 18 |  $ZLAB | Zai Lab Ltd | $3.5M | 1.6% | +0% | — |
| 19 |  $BIOA | BioAge Labs, Inc. | $2.5M | 1.1% | NEW | 26.8 |
| 20 |  $LBRX | LB PHARMACEUTICALS INC | $2.2M | 1.0% | NEW | — |
| 21 |  $EVMN | Evommune, Inc. | $1.6M | 0.7% | -35% | 14.9 |
| 22 |  $ACET | Adicet Bio, Inc. | $1.4M | 0.6% | +0% | — |
New Positions (3)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for NEXTBio Capital Management LP including:
Track NEXTBio Capital Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for NEXTBio Capital Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: NEXTBio Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For NEXTBio Capital Management LP (SEC CIK: 2038158), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in NEXTBio Capital Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.